Click HERE to complete the evaluation survey and receive your certificate.
References
The Evolving Goals of T2D Management in Primary Care
Ndumele CE, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-1635.
Marassi M and Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;22:195.
Wong K, et al. Comparison of demographic factors and cardiovascular risk factor control among us adults with type 2 diabetes by insulin treatment classification. J Diabetes Complications. 2012;26:169-174.
Feng X, et al. CKD Prevalence Among Patients With and Without Type 2 Diabetes: Regional Differences in the United States. Kidney Med. 2022;4(1):100385.
Burrows NR, et al. Reported Cases of End-Stage Kidney Disease — United States, 2000–2019. MMWR Morb Mortal Wkly Rep. 2022;71(11):412-415.
Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322.
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.
Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130.
Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420.
McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001-2012.
Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121.
American Diabetes Association Professional Practice Committee for Diabetes. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl_1):S183-S215.
GLP-1 RA-Based Therapies: Mechanisms, Evidence, and Differentiation
DeFronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes. 2009;58(4):773-795.
Miller E, et al. Type 2 diabetes: Evolving concepts and treatment. Cleve Clin J Med. 2019;86(7):494-504.
Andraos J, et al. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues. Rev Endocr Metab Disord. 2023;24(6):1089-1101.
Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102.
Byetta [Package Insert]. September 2025. Accessed June 8, 2026.
Victoza [Package Insert]. October 2025. Accessed June 8, 2026.
Bydureon Bcise [Package Insert]. May 2025. Accessed June 8, 2026.
Trulicity [Package Insert]. March 2026. Accessed June 8, 2026.
Ozempic [Package Insert]. Updated October 2025. Accessed June 8, 2026.
Ozempic, Rybelsus [Package Insert]. January 2026. Accessed June 8, 2026.
Mounjaro [Package Insert]. Updated January 2026. Accessed June 8, 2026.
Heuvelman V, et al. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res. 2020;116(5):916-930.
Hammoud R, et al. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19(4):201-216.
Deis T, et al. Gut Hormones in Heart Failure. Circ Heart Fail. 2024;17(11):e011813.
Shchendrygina A, et al. Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life. Card Fail Rev. 2024;10:e10.
Packer et al for the SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392:427-437.
Krüger N, et al. Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction. JAMA. 2025;334(14):1255-1266.
De Boer, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102(5):974-989.
Wexler et al. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes. The GRADE Randomized Clinical Trial. JAMA Internal Medicine. 2023;183(7):705-714.
Targher, et al. Metabolic Dysfunction–Associated Steatotic Liver Disease. N Engl J Med. 2025;393(7):683-698.
Cusi K, et al. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-1082.
Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099.
Egan AG, et al. Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment. N Engl J Med. 2014;370:794-797.
Ramsey DJ, et al. GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes. JAMA Netw Open. 2025;8(8):e2526321.
Shor R, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2025;143(7):587-594.
Hsu AY, et al. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes. JAMA Ophthalmol. 2025;143(5):400-407.
Practical Implementation and Overcoming Barriers
American Diabetes Association Professional Practice Committee for Diabetes. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl_1):S183-S215.
Gorgojo-Martínez JJG, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022;12(1):145.
Boye K, et al. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study. Diabetes Obes Metab. 2021;23(2):508-519.
Almandoz JP, et al. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clin Diabetes. 2020;38(4):390-402.
Jain AB, et al. Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance. Int J Clin Pract. 2021;75(2):e13731.
What’s Next: Innovations and Emerging GLP-1 RA–Based Options
Aroda VR, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402(10403):693-704.
Rosenstock J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(11):1065-1076.
Lingvay I, et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935-948.
Lv L, et al. Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting. Prim Care Diabetes. 2024;18(5):511-517.
Boye K, et al. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study. Diabetes Obes Metab. 2021;23(2):508-519.
Dehestani B, et al. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 2021;30(4):320-325.
Davies MJ, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-659.
Winther JB, et al. Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity. Diabetes Obes Metab. 2024;26(9):3501-3512.
Samms RJ, et al. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity. Diabetes. 2025;74(8):1326-1333.
Hay DL, et al. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015;67(3):564-600.
Buse JB, et al. Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026 Jun 7:S2213-8587(26)00125-7.
Rosenstock J, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026 Jun 7:S0140-6736(26)01022-6.
Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026 Jun 6:S0140-6736(26)00967-0.
Zhu D, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026;652(8108):174-180.
Guo L, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026;652(8108):181-188.
PR Newswire. Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3. October 26, 2025. Accessed June 8, 2026.
GlobeNewswire. Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes. November 25, 2025. Accessed June 8, 2026.
Resource Toolkit
Access & Affordability of Medications: Techniques to Deal with Financial Burden
To view a presentation on access and affordability of medications, click HERE.